We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 12 for:    istar | Glaucoma
Previous Study | Return to List | Next Study

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. (STAR-V)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05024695
Recruitment Status : Recruiting
First Posted : August 27, 2021
Last Update Posted : August 27, 2021
Sponsor:
Information provided by (Responsible Party):
iSTAR Medical

Brief Summary:
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.

Condition or disease Intervention/treatment Phase
Glaucoma Device: MINIject™ Implant Not Applicable

Detailed Description:
This is a prospective, multicenter, masked clinical trial to evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 975 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space. The MINIject™ SO627 implant is manufactured from proprietary STAR® silicone material.
Masking: None (Open Label)
Masking Description: Person(s) checking intraocular pressures are masked, except for day of surgery, throughout the duration of the trial.
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter Masked Clinical Trial to Evaluate the Safety and Effectiveness of the MINIject CS627 Implant in Subjects With Open Angle Glaucoma
Actual Study Start Date : August 19, 2021
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : March 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: Implant Group Device: MINIject™ Implant
The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.




Primary Outcome Measures :
  1. Intraocular pressure decrease [ Time Frame: 24 months ]
    Proportion of subjects with ≥ 20% decrease (responders) from Baseline in unmedicated DIOP at Month 24.

  2. Intraocular pressure decrease (outcome 2) [ Time Frame: 24 months ]
    Change from baseline in mean unmedicated diurnal IOP at Month 24.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   46 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Males and females, 46 years of age or older
  • A diagnosis of primary open-angle glaucoma, who are candidates for medical therapy, laser treatment, or glaucoma-filtering surgery
  • Pseudophakic with prior uncomplicated cataract surgery

Key Exclusion Criteria:

  • Angle closure, congenital, or secondary glaucoma
  • Diagnosed degenerative visual disorders
  • Clinically significant intraocular inflammation or infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05024695


Contacts
Layout table for location contacts
Contact: Abhi Vilupuru, Ph.D 714-914-5527 abhi.vilupuru@istarmed.us

Locations
Layout table for location information
United States, Arkansas
Vold Vision Recruiting
Fayetteville, Arkansas, United States, 72704
Contact: Steve Vold         
Principal Investigator: Steve Vold, M.D.         
Sponsors and Collaborators
iSTAR Medical
Investigators
Layout table for investigator information
Study Chair: Abhi Vilupuru, Ph.D iSTAR Medical
Layout table for additonal information
Responsible Party: iSTAR Medical
ClinicalTrials.gov Identifier: NCT05024695    
Other Study ID Numbers: ISM06
First Posted: August 27, 2021    Key Record Dates
Last Update Posted: August 27, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by iSTAR Medical:
glaucoma
MIGS
primary open angle glaucoma
suprachoroidal space
supraciliary space
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases